The biotech industry has evolved significantly since Diamond v. Chakrabarty in 1980 and the IP protections afforded it have evolved similarly. Generally, most biotech companies do not produce products. Rather, they derive their income from the earnings or future earnings of the patents they hold. An entire company’s survival may well depend on its ability to develop its intellectual capital. In turn, management and investors depend on the ability of IP legal counsel to defend and protect those IP assets ensuring a company’s vitality and viability. CPLP has the broad legal experience and the specific scientific background to successfully navigate the many challenges members of the biotech industry face. The firm provides world-class litigation services, and approaches all IP matters as potential litigations to be won or avoided. Biotechnology companies rely on us to apply this approach in our substantial patent prosecution, licensing, opinion work and counseling practices.

“Keep It Candid at the USPTO,” Managing Intellectual Property - International Briefing

“How Seagate has reshaped patent litigation practices,” Managing Intellectual Property

“Recapturing R&D Leadership,” Industry Week

“Biosimilars in the United States - a Brief Look at Where We Are and the Road Ahead” from Biotechnology Law Report - Expert Analysis of Current Developments

Biosimilars in the United States: An Update, presented at Biosimilars 2007, organized by Visiongain, London, United Kingdom, December 6, 2007 (Lecture by Alan J. Morrison, Partner)

Understanding, Prosecuting and Enforcing Biotech and Pharmaceutical Patents in the United States, presented at the 2007 IP Workshop for Biotech Pharmaceutical Industry (Including Generic Drug Entry in the US), held under the auspices of the Center for Drug Evaluation, Taipei, Taiwan, April 2, 2007 (Lecture by Alan J. Morrison, Partner)